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Abstract: Globally, vitamin A deficiency (VAD) affects nearly 200 million children with negative
health consequences. VAD can be measured by a retinol-binding protein (RBP) and serum retinol
concentrations. Their concentrations are not always present in a 1:1 molar ratio and are affected by
inflammation. This study sought to quantify VAD and its impact on infant mortality and infectious
morbidity during the first 18 months of life in a cohort of mother-infant dyads in El Alto, Bolivia,
while accounting for the previously mentioned measurement issues. Healthy mother-infant dyads
(n = 461) were enrolled from two hospitals and followed for 12 to 18 months. Three serum samples
were collected (at one to two, six to eight, and 12 to 18 months of infant age) and analyzed for
RBP, and a random 10% subsample was analyzed for retinol. Linear regression of RBP on retinol
was used to generate RBP cut-offs equivalent to retinol <0.7 µmol/L. All measures of RBP and
retinol were adjusted for inflammation, which was measured by a C-reactive protein and alpha
(1)-acid glycoprotein serum concentrations using linear regression. Infant mortality and morbidity
rates were calculated and compared by early VAD status at two months of age. Retinol and RBP
were weakly affected by inflammation. This association varied with infant age. Estimated VAD
(RBP < 0.7 µmol/L) decreased from 71.0% to 14.8% to 7.7% at two, six to eight, and 12 to 18 months
of age. VAD was almost nonexistent in mothers. Early VAD was not significantly associated with
infant mortality or morbidity rates. This study confirmed a relationship between inflammation and
vitamin A biomarkers for some subsets of the population and suggested that the vitamin A status in
early infancy improves with age and may not have significantly affected morbidity in this population
of healthy infants.
Keywords: vitamin A deficiency; infant nutrition; micronutrient deficiencies; global micronutrient
malnutrition
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1. Introduction
Vitamin A deficiency (VAD) affects an estimated 190 million children under five years of
age worldwide with the greatest burden in low-income and middle-income countries (LMIC) [1].
Numerous critical biological functions are affected by vitamin A and deficiency can lead to increased
susceptibility to infections, night blindness, and even full vision loss [1]. Given the potentially severe
consequences of VAD, many countries have implemented supplementation and fortification programs
and the prevalence of VAD has declined over time [2]. Nonetheless, in many areas, VAD persists as
a public health problem while, in other areas, data on VAD prevalence is outdated or does not exist at
the national level [3,4].
Although vitamin A liver stores are the gold standard for the measurement of vitamin A status,
it is more common to use serum retinol or its carrier known as the retinol binding protein (RBP) as
a surrogate given the invasiveness of the liver biopsy and the time and resources required for relative
dose response tests to assess vitamin A total body stores [5,6]. Retinol levels <0.7 µmol/L are commonly
considered as representative of VAD in adults and children ≥6 months of age, and the prevalence of
individuals with serum retinol <0.7 µmol/L or RBP concentrations <0.7 µmol/L is used by the World
Health Organization to assess population VAD and to reflect the severity of VAD as a public health
problem [1,7]. RBP is considered to be similar in molar ratio (1:1) as retinol, which requires less volume
of blood to assay and is less expensive to measure [5,8]. Nonetheless, the ratio of retinol to RBP may be
affected by extraneous factors such as vitamin A status and inflammation, as well as a nutritional status
especially obesity [7,9,10]. Thus, it is important to evaluate this relationship in multiple populations.
Specifically, when a linear model is used to compare retinol to RBP in a population where both
are measured, correlations have ranged from 0.50 to 0.95, and molar ratios have been both above
and below one [11–16]. Furthermore, RBP and retinol are themselves affected by the acute phase
response (APR), which is the body’s inflammatory reaction to trauma, infection, or stress [17,18].
Specifically, both retinol and RBP have been shown to be depressed by as much as 40% in the presence
of inflammation—whether caused by trauma or infection. However, this relationship was recently
observed to be stronger in preschool children when compared to women [17,19–21]. Acute phase
proteins (APP) can be used to adjust retinol and RBP for the inflammatory effect, facilitating a more
accurate interpretation of a vitamin A status. The APPs C-reactive protein (CRP) and alpha(1)-acid
glycoprotein (AGP) are commonly used for this purpose [10,17,22].
Young infants are at higher risk of low vitamin A status than adults. Although fetuses accumulate
hepatic stores of vitamin A during the last trimester of pregnancy, infants are typically born with half
the circulating serum retinol as their mothers [23]. Because retinol can be teratogenic, women do not
receive high-dose supplementation during pregnancy. However, supplementation is common in the
immediate postpartum setting particularly because retinol is transferred into breastmilk through which
infants receive Vitamin A [24]. Infants, however, do not typically receive vitamin A supplementation
(VAS) until six months of age since systematic reviews have not indicated any morbidity or mortality
benefit of VAS before this time [25–27]. Few studies exist that longitudinally measure vitamin A status
between birth and 6 months of age, and the biomarker cut-offs used to assess vitamin A status in
older infants and children are not fully validated in infants below the age of 6 months. Consequently,
little is known about the evolution of the vitamin A status, the development and prevalence of VAD,
or the potential health effects of low vitamin A in healthy, exclusively breastfeeding infants before the
initiation of biannual supplementation.
The primary aim of the present study is to describe the vitamin A status in a cohort of
mother-infant dyads in El Alto, Bolivia. Specifically, we wished to explore the impact of inflammation
on RBP and retinol and to examine the relationship between these two biomarkers. A secondary
objective was to assess whether a low vitamin A status at two months of age (RBP < 0.7 µmol/L) had
any measurable impact on later infant mortality and rates of infectious morbidity. A tertiary objective
was to identify correlations of infant VAD to guide the potential impact of vitamin A programs.
Nutrients 2018, 10, 1240 3 of 17
This study will provide useful information from a population of individuals of primarily indigenous
descent residing at a high altitude in the setting of national micronutrient supplementation programs.
2. Methods
2.1. Study Population and Design
Data for the present study were drawn from the Nutrición, Inmunología, y Diarrea Infantil (NIDI)
study, which had a primary aim of assessing the effect of an infant nutritional status to respond to the
rotavirus vaccine (scheduled at 2 and 4 months of age). The study setting of El Alto (altitude 4000 m)
is a peri-urban locale home to a largely indigenous population in which most have relatively few
socioeconomic resources. As part of other maternal and child health programming, Bolivian policies
recommend vitamin A supplementation (VAS) to mothers immediately postpartum and to infants
every 6 months during the 6–59-month age range. Policies also provide for 60 sachets of multiple
micronutrient powder (MNP, “Chispitas”, 12.5 g iron as ferrous fumarate, 5 mg zinc as zinc gluconate,
300 µg vitamin A as retinol acetate, 30 mg vitamin C, 180 µg folic acid, intended for usage at
1 sachet/day), which is provided on the same twice-yearly schedule as child VAS [28]. Vitamin A
fortification of vegetable oil has been mandated in Bolivia since 2005, but not all neighboring countries
share this mandate, so levels vary for imported cooking oil. The brand of cooking oil used by
participants was not captured in the present study.
Study methods are described in detail elsewhere [29,30]. In brief, 461 healthy infants (2–4 weeks
of age) and their mothers were recruited from 2 hospitals during well-child or vaccination visits.
Infants were excluded in cases when immunodeficiency, congenital malformations, or acute illness
were suspected at the time of enrollment. Inclusion criteria included the maternal ability to speak
and understand Spanish or Aymara. Recruitment took place from May 2013 through March 2014.
Participants were followed for 12 to 18 months and final data were collected in March 2015. For any
infant who died during the period of study participation, a verbal autopsy was conducted to rule out
the relationship for the study activities.
The study comprised 7 hospital visits and 2 in-home visits. At each study visit, feeding
and supplementation practices were queried and mothers were asked whether their child had
experienced fever, respiratory illness/cough, diarrhea, or any other illness within the prior two
weeks. Mothers were also instructed to call the study staff if their child developed diarrhea between
study visits. A morbidity episode was defined as a report of one or more of these symptoms including
diarrhea reported between study visits. The exclusive breastfeeding status was based on a maternal
recall of feeding practices through the most recent visit. Exclusive breastfeeding was defined as
a maternal report of feeding the child only breast milk without any non-breast milk liquids or solid or
semi-solid foods.
Blood was drawn from mothers at a target schedule of 1 and 6 to 8 months postpartum and
from infants at a target schedule of 2 months, 6 to 8 months, and (optionally) 12 to 18 months of age.
The third infant blood draw, added to support a newly funded secondary aim, was approved only
after 50% of infants had already completed the study. These mothers were contacted to participate
optionally in an extra visit and a blood draw. At this time, mothers were also offered anemia testing for
themselves via a finger stick. Infants completing three blood draws were not meaningfully different
from those whose mothers did not consent to the third blood draw.
For the primary aim of assessing infants’ vitamin A status, all singleton infants with at least the
first blood draw were included for each time point where they had available data. For the secondary
aim of assessing potential consequences of early VAD (i.e., VAD at 2 months of age), the analytical
population included only singletons with the first blood draw who were followed until the time of the
second blood draw. Inclusion was not dependent on the success of the second blood draw. Mothers
were included at each time point based on whether they had available data.
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2.2. Ethical Approval
The protocol and instruments for this study were approved by the Emory University IRB
(IRB00056127) and the Bolivian Comité de Etica de la Investigación (Research Ethics Committee).
Mothers provided written informed consent in Spanish or Aymara after demonstrating an
understanding of the study goal and requirements.
Mothers and infants were referred to hospital clinicians for anemia, according to Bolivian
guidelines (hemoglobin < 13.7 g/dL for mothers, hemoglobin < 10.9 g/dL for infants and toddlers,
with no altitude adjustment) [28]. Infants were also referred for stunting (length-for-age Z score < −2)
or wasting (weight-for-length Z score < −2) as diagnosed by trained anthropometrists based on WHO
growth charts [31].
2.3. Laboratory Analysis
Venous blood was collected (1 mL) from mothers and infants using zinc-free syringes and tubes.
Hemoglobin (Hb) was measured at point-of-care using a HemoCue® Hb-201+ photometer. Plasma
was analyzed at the VitMin Lab by a sandwich ELISA for CRP (a marker of acute inflammation,
limit of detection [LOD]: 0.5 mg/L), AGP (a marker of chronic inflammation, LOD: 0.1 g/L), retinol
binding protein (RBP, LOD: 0.05 µmol/L), ferritin (Fer, LOD: 2 µg/L), and soluble transferrin receptor
(sTFR, LOD: 0.5 mg/L, Ramco assay equivalents, VitMin Lab, Willstaett, Germany) [8].
Given that retinol and RBP are not necessarily present in a 1:1 molar ratio, a random 10%
subsample (N = 172) of serum aliquots was selected for additional retinol testing. The subsample
was spread across mothers, infants, and all time points (N = 1736). Retinol was analyzed by
high-performance liquid chromatography (HPLC) by the Instituto de Nutrición de Centroamérica
y Panamá (INCAP) laboratory (Guatemala City, Guatemala). A retinol acetate internal standard was
used in each analytical run. Quality control (QC) samples in 3 levels (low, medium, and high) were
used in each analytical run. The inter-assay coefficient of variability (CV) was <10%. Serum control
samples (Liquicheck, Bio-Rad, Hercules, CA, USA) were used as standards for the calibration curve.
QC samples in two levels (low and high) were used in each analytical run. An inter-assay CV was <4%
for RBP. A CV of about 10% provides acceptable precision using an ELISA technique [8]. These data
indicate that the lab’s performance exceeded the acceptable performance expectations while analyzing
the survey specimens.
2.4. Definitions of Anemia, Inflammation, and Vitamin A Deficiency (VAD)
Hb cut-offs for anemia were adjusted for the high altitude (3500 to 4000 m) of El Alto and the
surrounding area of La Paz [32]. Anemia was defined as Hb < 13.7 g/dL for infants and as Hb < 14.7 g/dL
for mothers (14.4 g/dL for the 10 mothers who reported currently smoking, two mothers who were pregnant
at the last visit were excluded from analysis) based on WHO guidelines [33]. Inflammation was defined as
CRP > 5 mg/L or AGP > 1 g/L [17,34].
Serum retinol < 0.70 µmol/L is recommended to indicate populations at risk of VAD [1,35]. Given
that it is cheaper to measure, RBP is often used in a 1:1 molar ratio as a surrogate marker for retinol.
However, since RBP and retinol are not always present in a 1:1 molar ratio, we used linear regression of
RBP on retinol to determine the RBP equivalent of a retinol cutoff of <0.70 µmol/L. Using the estimated
parameters from this linear model, we solved the regression equation to determine the RBP equivalent
of 0.70 µmol/L retinol among infants and mothers. This regression did not take into account the
inflammation status of the individuals. The regression-calculated RBP cut-off was <0.33 µmol/L for
infants and <0.65 µmol/L for mothers. In the present analysis, we compared the VAD prevalence
using three different definitions: (1) serum retinol < 0.70 µmol/L, (2) serum RBP < 0.70 µmol/L,
and (3) serum RBP < 0.33 µmol/L (infants)/< 0.65 µmol/L (mothers). Through this method, we tested
the impact of assuming a 1:1 molar ratio for RBP to retinol given that this common assumption was
not valid for our population. Since a validated cutoff for VAD does not exist in children <6 months of
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age, we applied the cutoff of RBP < 0.70 µmol/L to classify these infants for the purposes of analyses
of “low Vitamin A status in early infancy”.
2.5. Adjustment of Vitamin A Biomarkers for Inflammation
Given the well-described effects of inflammation on RBP and retinol, we adjusted the biomarkers’
concentrations for CRP and AGP [17]. Based on the Biomarkers Reflecting Inflammation and
Nutrition Determinants of Anemia (BRINDA) project [36] and other publications [22,37], we employed
a correction method based on linear regression since it best accounts for the linear (or log-linear)
relationship between both CRP and AGP and RBP and, therefore, does not rely on arbitrary CRP
and AGP cutoffs [37]. For the body of the present paper, we present the crude (unadjusted) and
adjusted results. For each population subset (2-month-old infants, 6–18-month-old infants, mothers),
the vitamin A biomarker, i.e., RBP or retinol, (log-transformed to meet normality assumptions) was
modeled as a function of continuous CRP and AGP (also log-transformed to improve the model fit).
ln(RBP) = β0 + β1 ln(CRP) + β2 ln(AGP) (1)
In the above equation, the intercept (β0) represents the natural log of the counterfactual RBP that
would have been observed in the absence of inflammation. This equation is then solved for this quantity,
which is hereby denoted as ln (RBPcorr) to show that it is the estimated “inflammation-corrected” value
of the natural log of RBP. Similarly, we must account for the CRP and AGP that are above the “normal”
values. We do so by subtracting the chosen reference values from the observed values.
ln(RBPcorr) = ln(RBPobs)− ˆˆβ1(ln(CRPobs)− ln(CRPref))− ˆˆβ2(ln(AGPobs)− ln(AGPref)) (2)
Since there are no established reference values for normal CRP and AGP in the literature, the first
deciles of CRP and AGP in the populations were used as the reference values for the reported results.
This approach is consistent with decisions made by Larson et al. [19]. Given potential differences in
vitamin A metabolism as well as the acute phase response and, based on examination of the data, mothers
(1st deciles 0.44 mg/L CRP, 0.49 g/L AGP) were adjusted separately from infants (1st deciles 0.14 mg/L
CRP, 0.31 g/L AGP). The RBP and retinol values for the youngest infants were not adjusted at all since no
relationship was visually observed between inflammation and vitamin A biomarkers. Data from these
infants were also excluded from the data used to generate regression equations for older infants.
2.6. Statistical Methods
The relationships among RBP, retinol, AGP, and CRP were plotted and visually examined. RBP and
VAD were also plotted by the quintile of AGP and CRP to inform decisions on the adjustment for
inflammation. The Cochran-Armitage test for the trend was used to analyze whether the proportion
of uncorrected VAD varied by the APP quintile. To assess differences between continuous variables
(e.g., RBP) at different time points, the Wilcoxon signed-rank test was used given non-normal
distributions and paired data. To assess differences between categorical variables at different time
points, McNemar’s test for paired nominal data was used. Fisher’s exact test was used to test unpaired
categorical data. For the secondary objective of determining potential health consequences of low
vitamin A status in infants <6 months of age, the rates of morbidity episodes (report of cough, fever,
diarrhea, or other illness) between the first (2 months of age) and second (~6–8 months of age) blood
draws were compared between children VAD vs. non-VAD at the first blood draw (defined as RBP
<0.70 µmol/L). Morbidity rates were calculated for each child using the total number of unique
morbidity episodes reported by the child’s mother between the first and second blood draws over
the total time in the study between these two blood draws. As a secondary analysis, rates were also
compared for the time period between the first blood draw and the child’s final study visit. Poisson
models were used to compare morbidity rates between the two groups (modeling episode counts
with an offset of log (time on study) to calculate rate ratios and adjusting a priori for low birth weight
(<2500 g) as well as adjusting for maternal employment as a marker of socioeconomic status and
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inflammation-adjusted ferritin (as above) as a marker of iron status. All variables were retained in
each model (primary analysis: morbidity rates between the first and second blood draws, secondary
analysis: morbidity rates between the first blood draw and the final study visit). Crude mortality rates
were also calculated and compared for infants VAD at the first blood draw versus infants non-VAD
at the first blood draw by again utilizing the time period between the first and second blood draws
(i.e., 2 to 6 months of age, approximately). However, a post-hoc power analysis demonstrated low
power to detect differences in mortality (<10%) given the low number of deaths.
For the tertiary objective of identifying potential correlates of VAD in early life (as defined by
crude RBP <0.70 µmol/L at 2 months of age), logistic regression models for determining the vitamin A
status at the first blood draw were constructed using the following predictors selected a priori based
on literature review: infant age, exclusive breastfeeding, preterm birth, low birthweight, sex, infant
stunting, infant overweight or obesity, infant ferritin (a marker of iron status), maternal age, maternal
employment, maternal education, maternal self-identified ethnicity (indigenous vs. non-indigenous),
and maternal overweight. Since this was an exploratory exercise, the model was reduced using
backwards elimination based on the significance of effects with an alpha level of 0.05. Few data (~15%)
were missing. Cases with missing data on outcomes or predictors of interest were excluded from
models. Only data from the time point of the first blood draw were used in this analysis. Data were
cleaned (e.g., examination of outliers, exclusion of biologically improbable or logically inconsistent
values, and creation of new variables) and analyzed using SAS v9.4 (Cary, NC, USA) and the R
Environment for Statistical Computing [38].
3. Results
3.1. Characteristics of the Study Population
The study population for the analysis of VAD prevalence included 365 singleton infants with
data from the first blood draw. A total of 310 infants (85%) had data from the second blood draw,
and 168 infants (46%) had data from the third blood draw. Five twin pairs were excluded from analysis,
64 singleton infants were lost to follow up or excluded for failure to adhere to the vaccination schedule,
and 24 singletons were excluded for insufficient or failed blood draw. Among mothers, 455 had
data from the first blood draw (which occurred one month prior to the infants’ first blood draw),
and 363 infants had data from the second blood draw.
Infants were enrolled at an average age of one month with the first blood draw occurring at
an average of 2 months of age (Table 1). The gender distribution was fairly even, and one third of
infants were born via Caesarian section, one fifth were preterm, and less than one tenth were of
low birth weight. Nearly all infants were breastfed at some point and half were first-born children.
The mean maternal age was 25.4 years, and over half of the mothers were overweight or obese.
Most mothers had at least a secondary education and nearly all were married or cohabiting with
a partner. Socio-demographics varied among the sample, with only a quarter of households owning
a refrigerator but over half having access to a private toilet. Approximately three quarters of infants
were anemic, while stunting varied from 14% to 21% and overweight factors varied from 19% to 34%
(Table 2). Most infants continued breastfeeding through the first year of life. Among mothers, anemia
prevalence decreased from the first (30%) to the second (15%) blood draw.
3.2. Retinol, Retinol-Binding Protein, and Inflammation
Both retinol and RBP were weakly affected by the presence of inflammation and the strength and
direction of this association varied with infant age. In the youngest infants, a null or slight positive
effect was seen while, in older infants, retinol and RBP decreased in the presence of inflammation.
Slopes were similar for RBP and retinol as functions of CRP and AGP (data not shown). In the second
and third blood draws, the prevalence of VAD as defined by RBP <0.70 µmol/L significantly increased
with increasing APP quintiles. No such relationship was seen at the first blood draw (Figure 1).
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Table 1. Characteristics of the study population.
N or Mean± SD Frequency (%)
Infant Characteristics
Male 195 53.4
Caesarian section birth 104 28.5
Preterm (<37 weeks) 67 18.8
Low birth weight (<2500 g) 22 6.5
Birth interval < 36 months 1 60 17.0
Ever breastfed 362 99.2
Maternal Characteristics
Age (years) 25.4 ± 6.4 –
Primipara 218 47.9
Overweight or obese (Body Mass Index > 25 kg/m2) 225 57.5
Married or cohabiting with partner 395 86.8
Employed 116 25.6
Maternal Education
At least some secondary schooling 99 21.9
Completed secondary school 176 38.9
Incomplete secondary education 178 39.3
Household Characteristics
Number of people in household 5.1 ± 2.1 –
Refrigerator 117 25.7
High-quality flooring 2 148 32.5
Water piped inside home 168 36.9
Private toilet 261 57.4
1 Versus ≥ 36 months or firstborn. 2 Polished wood, parquet, rug, carpet, or tile (as compared to dirt, wooden
boards, cement, or brick).
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quintiles of the C-reactive protein (CRP) and the alpha(1)-acid glycoprotein (AGP) and by blood draw.
Panels (A–C) show VAD by CRP quintiles for blood drawn at ~2, 6–8, and 12–18 months, respectively.
Panels (D–F) show VAD by AGP quintiles for the same time periods. The prevalence of VAD was not
significantly differe t (Coc ran Armitage trend test, p = 0.23) by CRP quintile for infants measured at
the first blood draw (~2 months of age, pan l (A)) eve though VAD seemed to decr ase slightly by the
AGP quintile at the first blood draw (Cochran Armitage trend test, p = 0.0001, panel (D)). However,
prevalence of VAD significantly increased by CRP and AGP quintile for infants at the second and third
blood draws (6–8 and 12–18 months of age).
Nutrients 2018, 10, 1240 8 of 17
Table 2. Time-varying characteristics of the study population *.
2 Months † 6–8 Months 12–18 Months
N or Mean± SD Frequency (%) N or Mean± SD Frequency (%) N or Mean± SD Frequency (%)
Infants and Toddlers
N 365 – 310 – 168 –
Age 2.1 ± 0.3 – 6.7 ± 0.9 – 14.2 ± 2.3 –
Currently breastfed 357 ** 98.3 296 95.5 138 82.1
Received any vitamin A supplementation 0 0 130 41.9 165 98.2
Stunted (length-for-age Z scores [LAZ] < −2) 72 19.8 44 14.4 35 21.1
Overweight (weight-for-length Z score [WFL] > 1) 123 33.8 86 28.2 32 19.3
Anemia present ¥ 261 71.7 232 74.8 137 82.0
Inflammation present ‡ 10 2.7 65 21.0 27 16.1
Mothers
N 455 – 363 – – –
Overweight/obese £ 279 61.3 198 54.7 – –
Anemia present € 134 29.5 53 15.1
Inflammation present ‡ 160 35.2 65 17.9 – –
* All singleton infants with at least first blood draw. ** 214 (59%) exclusively breastfed. † Mothers measured at 1 month postpartum. ‡ CRP > 5 mg/L or AGP > 1 g/L. ¥ Using
altitude-adjusted WHO cutoff.£ BMI ≥ 25 kg/m2. € Using altitude-adjusted WHO cutoff (adjusted for smoking in smokers).
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In mothers, no clear relationship was observed between retinol and inflammation. There was
a small but significant negative relationship of RBP and CRP at the first postpartum visit (β = −0.1,
p < 0.0001), but RBP was otherwise not significantly associated with inflammation in mothers.
There was no relationship between the RBP and the APP quintile (Figure 2).
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3.4. Potential Consequences of Low Vitamin A Status in Early Life
Two of the infants in the analysis population died after the first blood draw. The crude mortality
rate among infants who were VAD at 2 months of age was 1.9/1000 child-months as compared to
0/1000 child-months among infants non-VAD at 2 months of age (using unadjusted RBP < 0.70 µmol/L
as the definition of VAD). However, the effect was not statistically significant and, due to the low
numbers, a rate ratio could not be calculated. The overall morbidity rate was 7.9 episodes (of fever,
respiratory illness, or diarrhea) per 100 child-months (Table 4). The morbidity rate for infants classified
as VAD at the first blood draw (using unadjusted RBP <0.70 µmol/L) was not significantly different
from the rate for infants classified as non-VAD at that blood draw (RR: 0.94, 95% CI: (0.82, 1.09),
p = 0.41). Secondary analyses using morbidity information up through 12 months of age did not
have different conclusions. While the point estimates for the rates were different, the rate ratio was
very similar.
3.5. Potential Correlations with Low Vitamin A Status in Early Life
Based on logistic regression models for this tertiary objective, only exclusive breastfeeding
(aOR: 1.10, 95% CI: (1.01, 1.21), p = 0.038) and age (aOR: 0.80 (0.68, 0.95) for a one-month increase,
p = 0.01) were significantly associated with VAD (as defined by RBP <0.70 µmol/L) at the first blood
draw (~2 months of age, N = 259/365 (71%)). Anemia was not significantly associated with a vitamin A
status at the first blood draw.
Nutrients 2018, 10, 1240 11 of 17
Table 3. Infant and maternal vitamin A status by biomarker and cut-off at different time points.
Retinol-Binding Protein (RBP) Retinol
Time Point N Crude Adjusted ‡ N Crude Adjusted ‡
Continuous RBP
(Mean± SD) VAD
Continuous RBP
(Mean± SD) VAD
Continuous Retinol
(Mean± SD) VAD
Continuous Retinol
(Mean± SD) VAD
Infants <0.33 µmol/L <0.7 µmol/L <0.33 µmol/L <0.7 µmol/L <0.7 µmol/L <0.7 µmol/L
2 Months 365 0.63 ± 0.15 0 (0%) 259 (71.0%) – – – 38 0.95 ± 0.24 7 (18.4%) – –
6–8 Months 310 0.84 ± 0.22 0 (0%) 88 (28.4%) 0.91 ± 0.23 0 (0%) 46 (14.8%) 29 1.21 ± 0.33 2 (6.9%) 1.39 ± 0.37 0 (0%)
12–18 Months 168 0.90 ± 0.23 0 (0%) 26 (15.5%) 0.97 ± 0.24 0 (0%) 13 (7.7%) 9 1.27 ± 0.37 0 (0%) 1.46 ± 0.34 0 (0%)
Mothers <0.65 µmol/L <0.7 µmol/L <0.65 µmol/L <0.7 µmol/L <0.7 µmol/L <0.7 µmol/L
1 Month postpartum 455 1.73 ± 0.54 3 (0.7%) 4 (0.9%) 1.83 ± 0.56 3 (0.7%) 3 (0.7%) 45 1.88 ± 0.46 0 (0%) 2.04 ± 0.49 0 (0%)
6–8 Months
postpartum 363 1.62 ± 0.44 1 (0.3%) 1 (0.3%) 1.69 ± 0.44 1 (0.3%) 1 (0.3%) 37 1.96 ± 0.36 0 (0%) 2.09 ± 0.39 0 (0%)
VAD: Vitamin A Deficiency. Cut-offs employed are indicated in boldface. ‡ Adjusted using linear regression with coefficients derived from data pooled across second and third blood
draws for infants and first and second blood draws for mothers. First blood draw values are not adjusted for infants given the observed lack of correlation between inflammatory
biomarkers and vitamin A biomarkers.
Table 4. Effects of early vitamin A deficiency (VAD; RBP < 0.70 µmol/L) on rates of reported morbidity episodes (N = 330) *.
Crude Adjusted **
Estimate 95% CI p-Value † Estimate 95% CI p-Value †
Rates (Morbidity episodes per 100 child-months)
Overall population 7.89 (7.41, 8.39) – – – –
Non-VAD at 2 months 8.22 (7.35, 9.19) – 8.65 (7.01, 10.68) –
VAD at 2 months 7.75 (7.20, 8.35) – 8.13 (6.78, 9.76) –
Rate Ratio 0.94 (0.82, 1.08) 0.39 0.94 (0.82, 1.09) 0.41
* Morbidity episodes included fever, respiratory illness/coughing, or diarrhea. ** Adjusted for maternal employment, low birth weight (<2500 g), and inflammation-adjusted ferritin.
† Wald Chi Square.
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4. Discussion
The present longitudinal study, which was conducted in a moderate-inflammation setting,
demonstrated a weak relationship between inflammation and biomarkers of vitamin A status
(e.g., serum retinol and RBP) especially among the maternal population. Among infants 2 months of
age, there was a moderate to high prevalence of low vitamin A status when measuring RBP or retinol
<0.70 µmol/L, which is a cut-off that has often been used in older populations. Consistent with our
current understanding of Vitamin A in infants, the prevalence of VAD sharply decreased as infants
aged. However, using the new cut-off generated from the RBP-retinol comparison indicated that VAD
was not present at all in these infants at any time point. VAD was virtually non-existent among mothers
using any definition. Early-life VAD as defined by 2-month RBP <0.70 µmol/L did not appear to affect
the rate of subsequent infectious morbidity episodes among infants. Although both infants who died
after the first blood draw had low vitamin A status, this effect was not significant perhaps due to the low
sample size. Only infant age (negative association) and exclusive breastfeeding (positive association)
were significant predictors of the vitamin A status at the first blood draw (~2 months of age).
In our study population, RBP and retinol were only weakly linearly associated with CRP and
AGP especially in mothers. These findings were similar to those in the BRINDA analysis of RBP and
APP [19]. For infants in our study population, the associations varied by age at blood draw: there was
no clear relationship at 2 months of age, but the expected negative relationship was present at older
ages. This may reflect the development of the immune system towards a more pro-inflammatory
state [39]. Generally, it may be that linear regression is insufficient to fully characterize the effect of the
acute phase response on vitamin A biomarkers. It could also be that our sample size (and majority
healthy population) allows for too much influence from outliers. A wider range of inflammatory states
may have allowed clearer visualization of a trend [17]. Furthermore, it is possible that the higher
prevalence of obesity and overweight in our population (>50% of mothers, >19% in infants) may have
modified the inflammatory effect since obesity is a known pro-inflammatory condition [40]. Lastly,
interpretation was particularly limited for retinol given the low number of data points especially when
stratified by age.
In this cohort, estimates of VAD among infants were sharply different by biomarker, cut-off,
and adjustment. Differences by biomarker and cut-off highlight the fact that RBP and retinol were
not present in a 1:1 molar ratio in this population, which is evidenced by the calculated cut-off of
<0.33 µmol/L (as opposed to the retinol cut-off of <0.70 µmol/L). Remaining differences in VAD
prevalence when comparing retinol <0.7 µmol/L to RBP <0.33 µmol/L may be explained by the
low sample size used to generate this cut-off, which may have been unduly influenced by outliers.
These findings underscore the importance of including an adequate retinol sub-sample (at least 10%
but preferably more) in any vitamin A study to validate cut-offs. Our data-generated cut-off was very
different from others that have been generated and used, which suggests that use of a literature-based
cut-off may be insufficient given potential differences in study populations [9,10,22].
In our study of primarily term and normal birthweight infants, we noted a marked improvement
in vitamin A status with an increasing infant age. This is consistent with other studies including higher
proportions of preterm and low birthweight infants [41,42] as well as a longitudinal study following
older, term infants [43]. This trend may reflect the biologic deficit at birth [23] as well as the impact of
vitamin A sourced from breastmilk in early infancy and supplementation or consumption of fortified
foods as infants age. While patterns among very low birthweight and preterm infants have not been
as clear [44,45], it may be that neither RBP nor retinol are good measures of vitamin A status among
young, preterm infants [46].
The estimated level of VAD in older infants when using the commonly used cut-off of RBP
<0.70 µmol/L was comparable to other countries in the region (in the middle or lower range) regardless
of the adjustment for inflammation [3]. The estimated level in mothers was on the lower end of
the range seen in the region [3], which may indicate successful implementation of fortification and
supplementation in women of reproductive age. For the youngest infants, VAD was high when defined
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as RBP <0.70 µmol/L or serum retinol <0.70 µmol/L but non-existent when using the calculated RBP
cut-off of 0.33 µmol/L. However, early-life low RBP was not significantly associated with morbidity or
mortality rates, which suggests that, even if vitamin A status was truly low in this population, it did
not have an adverse effect. This is consistent with previous research that failed to find a significant
effect of early-life (<6 months of age) VAS on infant morbidities or mortality [27]. It is recognized that
very young infants tend to have low vitamin A stores, and it may be that low vitamin A status does
not cause ill effects unless it remains low through older infancy and childhood. In the present study,
exclusive breastfeeding was significantly associated with VAD at approximately two months of age.
Evidence from other populations has been mixed [47–49]. This finding may be the result of chance,
uncontrolled or residual confounding, or a biological relationship that remains unclear.
This study was conducted among a relatively healthy population exposed to vitamin A through
fortified staples, MNPs, and supplementation and the generalizability of our findings should be
considered within that context. Even though the population is not representative of Bolivia as a whole,
the prevalence of obesity, the level of education, and other sociodemographic markers are in line with
urban Bolivian populations especially in this area as per DHS [50]. Our work has several strengths.
First, the longitudinal design enabled us to track the vitamin A status among a cohort of healthy,
primarily breastfed infants across a full year of life. Furthermore, we also measured CRP and AGP,
which allowed us to assess the relationship of inflammation to vitamin A biomarkers and explore the
impact of adjusting RBP and retinol for this relationship. Last, the measurement of retinol in addition
to RBP permitted the comparison of RBP to retinol and the calculation of a new cut-off that could
be applied to RBP and thereby account for a non-1:1 molar relationship between the two vitamin A
biomarkers. Nonetheless, the study was limited in that we were able to test only a 10% sample for
retinol. Therefore, relationships between retinol and inflammation were harder to quantify precisely
especially when samples were stratified by age or the mother-infant status. Furthermore, retinol and
RBP are most appropriate for population measurements. A modified relative dose response (MRDR)
is best for diagnosing individual VAD but was not performed. However, the purpose of this study
was not to assess the effect of vitamin A supplementation, and any VAD misclassification is likely
to be non-differential by exposures tested. As in any model, there exists the possibility of residual
or unmeasured confounding in our analysis of the effect of early-life VAD on the morbidity and
mortality rates as well as in the analysis of predictors of early-life VAD. Furthermore, the mortality
analysis was reduced in power due to the rarity of this outcome. Lastly, there is no gold standard for
adjusting nutritional biomarkers for inflammation. Our method takes into account the (log) linear
relationship between inflammation and RBP and retinol, and previous research has not identified
significant interaction [51]. However, there is a possibility that there may be other potential modifiers
or confounders of this relationship whose inclusion in the adjustment model would enable better
correction of vitamin A biomarkers for the effect of inflammation. For instance, it is possible that
vitamin D status, which was not measured but may be low in this high-altitude population could have
acted as a confounder of the RBP-CRP relationship [52]. The presence of genetic differences in retinol
metabolism could have also potentially obscured the relationships tested [53,54]. Lastly, while the
direct effect of inflammation on vitamin A biomarkers is well known, it is possible that there was an
additional effect of a low vitamin A status on inflammation (through increased vulnerability to an
infectious disease) that was not captured.
5. Conclusions
This study confirmed some relationships between inflammation and vitamin A biomarkers but
suggested that this relationship may not be fully described by linear regression or other commonly
used adjustment methods. The marked difference between the 1:1 molar ratio VAD cut-off (0.7 µmol/L)
and the data-generated cut-off (0.33 µmol/L) also underscored the importance of study-specific retinol
validation of RBP where resources allow. Lastly, the study suggested that a low vitamin A status in
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early infancy (~2 months of age) may not have significant effects on morbidity and is likely to improve
as infants age and increase their retinol intake via feeding or supplementation.
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